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Randomized Phase II Study of Maintenance Irinotecan
Therapy Versus Observation Following Induction
Chemotherapy with Irinotecan and Cisplatin in Extensive
Disease Small Cell Lung Cancer
Ji-Youn Han, MD, Heung Tae Kim, MD, Kun Young Lim, MD, Sung Jin Yoon, RN, Dae Ho Lee, MD,
and Jin Soo Lee, MD
Introduction: To determine whether irinotecan maintenance ther-
apy in extensive disease-small cell lung cancer can improve survival
of patients who responded to irinotecan plus cisplatin (IP) induction
therapy.
Methods: A total of 120 chemo-naive patients with adequate organ
functions and Eastern Cooperative Oncology Group performance
status of 0 to 2 were enrolled from March 2003 through April 2006.
After IP induction therapy, with either schedule A (I: 60 mg/m2
intravenously (IV) on days 1, 8, and 15; P: 30 mg/m2 IV on days 1
and 8, every 4 weeks for six cycles) or schedule B (I: 60 mg/m2 and
P: 30 mg/m2 IV on days 1, and 8, every 3 weeks for eight cycles),
responding patients were randomized to either maintenance with
irinotecan 100 mg/m2 IV on days 1, 8, and 15, every 4 weeks up to
six cycles, or observation.
Results: Overall, 100 (83%) of 120 patients achieved objective tumor
responses (12 complete responses, 88 partial responses) after IP induc-
tion therapy. Of those patients who remained in remission upon com-
pletion of planned cycles of induction therapy, 45 were randomized to
maintenance (n 21) or observation (n 24). Median progression-free
survival (PFS) and overall survival (OS) for all patients were 7.2 and
14.0 months, respectively. For the maintenance arm, median PFS and
OS were 12.0 and 17.6 months, respectively. For the observation arm,
median PFS and OS were 9.9 and 20.5 months, respectively, which was
not significantly different from the maintenance arm.
Conclusions: IP chemotherapy is very useful for the treatment of
small cell lung cancer. However, maintenance irinotecan therapy did
not seem to further affect the clinical outcome of patients who had
responded to IP induction therapy.
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Small cell lung cancer (SCLC) accounts for 13 to 15% ofall lung cancer and more than 60 to 70% of patients
present with extensive disease (ED).1 Although etoposide
plus cisplatin (EP) regimen has been the mainstay of ED-
SCLC treatment, median survival is about 9 months, with 5 to
10% surviving 2 years and only 1% of patients achieving a
long-term disease-free survival.2 To improve this outcome
further, various attempts have been made, which included
dose intensification with stem cell supports,3,4 maintenance
chemotherapy,5–19 and also searches for a better chemother-
apy regimen.20
Irinotecan has been demonstrated to have significant ac-
tivity against SCLC and a phase II trial conducted by the West
Japan Thoracic Oncology Group showed irinotecan plus cispla-
tin (IP) regimen had promising results. For previously untreated
patients with ED-SCLC, the objective response rate was 86%
with complete response (CR) rate of 26%.21 A subsequent
randomized phase III from the Japanese Cooperative Oncology
Group reported a statistically superior benefit of IP combination
over the standard EP chemotherapy. The median survival and
2-year survival rates on IP and EP arms were 12.8 months versus
9.4 months and 19.5% versus 5.2%, respectively.22 From a
separate randomized phase III trial, however, Hanna et al.23
reported no significant difference between IP and EP in response
rate and survival in 331 patients enrolled from the United States,
Australia, and Canada. On the other hand, Hermes et al. reported
in 2007 a randomized phase III study of irinotecan plus carbo-
platin versus etoposide plus carboplatin in 220 Norwegian and
Swedish patients with ED-SCLC. Similar to the Japanese Co-
operative Oncology Group data, they found a statistically sig-
nificant difference in overall survival (OS) in favor of the
irinotecan-containing regimen. Moreover, significantly more
CRs were observed with irinotecan plus carboplatin therapy.24
These findings suggest that irinotecan plus platinum agent che-
motherapy can improve the survival of ED-SCLC.
Regarding the role of maintenance chemotherapy in
SCLC, there have been about 14 randomized phase III trials
since 1980.6–19 Although its role remains unresolved until
recently and quite controversial, at least five studies had
found better progression-free survival (PFS) with mainte-
nance chemotherapy12,15,16,18,19 and three trials demonstrated
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statistically significant advantage for OS with maintenance
chemotherapy when only the patients who achieved objective
responses to induction chemotherapy were included.6,8,14
Given the documented contribution of irinotecan in the
treatment of SCLC, we postulated that irinotecan maintenance
therapy might improve the outcome of ED-SCLC patients who
achieved objective responses after IP induction therapy. There-
fore, we conducted a randomized phase II trial to examine
whether the irinotecan maintenance therapy would improve the
survival of ED-SCLC patients who responded to IP induction
chemotherapy.
PATIENTS AND METHODS
Eligibility criteria were as follows: (1) histologically con-
firmed SCLC; (2) extensive-stage disease; (3) Eastern Cooper-
ative Oncology Group performance status (PS) of 0 to 2;
(4) age 18 years old; (5) adequate function of bone marrow
(white blood cell count 4000/mm3 and platelet count
100,000/mm3), liver (bilirubin level 1.5 mg/dl, AST, and
ALT 2  the upper limit of normal), and kidney (creatinine
level 1.5 mg/dl); (6) at least one bidimensionally measurable
disease; (7) absence of active infection; (8) no prior chemother-
apy or radiotherapy; (9) no history of myocardial infarction in
the last 6 months, no congestive heart failure or significant
arrhythmia; (10) no second primary cancer, except skin cancer.
Patients with CNSmetastasis were eligible as long as neurologic
symptoms were controlled by corticosteroid.
All patients signed informed consent. The study was
approved by the institutional review board of our institution
and was conducted in compliance with institutional review
board regulations.
Treatment
Treatment was given in the outpatient setting, the
schema of which is shown in Figure 1. The first 40 patients
were treated with irinotecan 60 mg/m2 intravenously (IV) on
days 1, 8, and 15, and cisplatin 30 mg/m2 IV on days 1 and
8 of a 28-day cycles (schedule A). Because of frequent
omission of day 15 irinotecan and delay in the next cycle of
chemotherapy, next 80 patients were treated with irinotecan
60 mg/m2 and cisplatin 30 mg/m2 IV on days 1 and 8 of a
21-day cycle (schedule B). Patients received IP indu chemo-
therapy up to maximum six (schedule A) or eight cycles
(schedule B) for a total of 24 weeks unless there were disease
progression or undue toxicity. Toxicity was graded according
to the National Cancer Institute Common Toxicity Criteria
version 2.0. Response assessment was performed every three
cycles or whenever clinically indicated according to the
World Health Organization criteria.
Approximately 3 to 4 weeks after the last course of
induction IP chemotherapy, responding patients were ran-
domized to receive either irinotecan maintenance or observa-
tion alone. Stratification factors were response to induction
chemotherapy [CR versus partial response (PR)] and number
of metastasis site (0–1 versus 2 or more). Previously a phase
I study reported that the recommended dose of single-agent
irinotecan was 100 to 125 mg/m2 once a week.25 Addition-
ally, Masuda used irinotecan 100 mg/m2 every week to treat
Induction chemotherapy
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Irinotecan  (60 mg/m2) IV on day 1, 8, & 15
Cisplatin  (30 mg/m2) IV on day 1 & 8
Every 4 weeks X 6 cycles
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Observation 
(n=24) or
Maintenance (n=21)
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FIGURE 1. Study scheme. CR,
complete response; PR, partial
response; SD, stable disease;
PD, progressive disease.
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16 patients with refractory or relapsed SCLC, and 7 of 15
evaluable patients responded to irinotecan.26 Based on these
data, patients received irinotecan 100 mg/m2 IV on days 1, 8,
and 15, every 4 weeks up to six cycles as the maintenance
therapy. Follow-up consisted of physical examination, blood
cell counts, and chest radiographs every cycle and chest CT
every three cycles. The same follow-up was applied to both
arms when treatment was terminated. Choice of subsequent
treatment for progression was left to the discretion of the
investigator.
Statistical Analysis
Patients were randomized to one of two treatment arms
(maintenance or observation) following irinotecan/cisplatin in-
duction in equal proportions using a stratified permuted block
randomization. Patients were stratified according to response to
induction chemotherapy (CR versus PR) and number of metas-
tasis site (0 or 1 versus 2 or more). The primary endpoint of the
study was PFS. The secondary end point was evaluation of the
toxicity to maintenance irinotecan following irinotecan/cisplatin
induction chemotherapy and OS. This trial was designed to
detect an increase in median PFS from 7 to 12 months in
responding patients receiving maintenance chemotherapy ( 
0.05,   0.02, one-tailed test) and required accrual of 50
assessable patients for each arm. Assuming the objective re-
sponse rate of 85%, we initially planned accrue a total of 120
patients. Survival time and PFS were defined from the date on
which the study began until date of death (or date last seen) or
date of progression, respectively. Survival curves were con-
structed using the Kaplan–Meier product limit method.
RESULTS
Patients
From March 2003 through April 2006, 120 patients were
entered in this trial. Patients’ characteristics are listed in Table 1.
Out of 100 responding patients (CR or PR), 63 patients main-
tained objective tumor responses after a total of six or eight
cycles of IP induction therapy. The other 37 initially responding
patients became not eligible for randomization because of dis-
ease progression during induction therapy. Among 63 patients
maintaining tumor responses, 45 patients were randomized to
either maintenance irinotecan single therapy or observation. The
other 18 patients were not randomized for the following reasons:
14 patients’ refusal due to either declined PS or toxicities, and 4
due to follow-up loss. Twenty-one patients were randomized to
irinotecan maintenance arm and 24 were to observation arm.
Patient characteristics at the time of randomization are also
depicted in Table 1.
Treatment Delivery
The median number of induction IP chemotherapy cycles
delivered was six (range, 1–8). By treatment schedule, 80%
(32/40) of patients completed six cycles of IP chemotherapy in
schedule A. In schedule B, 38% (30/80) of patients completed
eight cycles and 63% (50/80) of patients received more than six
cycles of IP chemotherapy. The reasons for treatment discontin-
uation were disease progression (5% for schedule A, 34% for
schedule B), toxicity (5% for schedule A, 23% for schedule B),
and follow-up loss (10% for schedule A, 6% for schedule B).
The median number of maintenance irinotecan single
chemotherapy cycles delivered was three (range, 1–6). Only
5 of 21 (24%) of patients completed all six cycles. The
remaining patients did not complete maintenance irinotecan
therapy because of PD (nine), pneumonia (two), poor PS
(two), prolonged thrombocytopenia (one), acute myocardial
infarction (one), and patient’s refusal (one).
Toxicity
One hundred nineteen patients were included in evalu-
ation of toxicity of induction IP chemotherapy. Overall,
toxicity of induction therapy with IP was similar to our
previous report.4 Myelosuppression was the most common
grade 3 or 4 toxicity and grade 3 diarrhea developed in 13
(12%) patients (Table 2). There were five treatment-related
deaths (4%) that occurred after the first cycle of IP, three due
to sepsis with neutropenia, and two due to pneumonia.
Maintenance with irinotecan was well tolerated. My-
elosuppression was the most common grade 3 or 4 toxicity,
with anemia reported in 28.6% of patients and granulocyto-
penia in 28.6% of patients (Table 3). Nonhematologic toxic-
ity was mild. There was no treatment-related death during
maintenance irinotecan therapy.
Response
Of a total 120 patients, 12 patients (10%) achieved CR
and 88 patients (73%) achieved a PR, for an overall response
rate of 83%. Three patients (3%) maintained SD, and 17
TABLE 1. Patients’ Characteristics
Characteristics
Total
(n  120)
n (%)
Maintenance
(n  21)
n (%)
Observation
(n  24)
n (%)
Age, median (range) 63 (33–79) 63 (51–77) 63 (51–77)
Sex
Male 107 (89) 19 (91) 23 (96)
Female 13 (11) 2 (9) 1 (4)
ECOG PS
0 24 (20) 4 (19) 4 (17)
1 64 (53) 12 (57) 16 (66)
2 32 (27) 5 (24) 4 (17)
No. of metastatic sites
1 68 (57) 16 (76) 18 (75)
1 52 (43) 5 (24) 6 (25)
Induction schedule
Every 4 wk 40 (33) 11 (52) 13 (54)
Every 3 wk 80 (67) 10 (48) 11 (56)
Response to induction
CR 12 (10) 4 (19) 6 (25)
PR 88 (73) 17 (81) 18 (75)
SD 3 (3) 0 0
PD 5 (4) 0 0
NA 12 (10)
NA, nonassessable.
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patients (14%) had treatment failure, which include 5 patients
who developed PD during IP chemotherapy, 7 who stopped
therapy due to toxicity or noncompliance, and 5 patients who
died during the first cycle of IP chemotherapy.
Of the 21 patients randomized to maintenance irinote-
can therapy, all were evaluable for response: 2 remain in CR,
7 remained in PR, whereas 12 had PD during the 6-month
period of maintenance irinotecan therapy. In the observation
arm (n  24), 2 remained in CR, 3 remained in PR, whereas
19 had PD during the same 6-month period (Table 4).
Survival
After median follow-up of 39.1 month (range, 15.2–
52.7), 19 of 120 patients were known alive at the time of this
report. Median OS for all patients was 14 months [95%
confidence interval (CI), 12.5–15.7] with 1- and 2-year sur-
TABLE 2. Maximal Hematologic and Nonhematologic Toxicity of Induction
Chemotherapy per Patient (n  119)
Grade by NCI-CTC Version 2.0
0 1 2 3 4
n (%) n (%) n (%) n (%) n (%)
Hematologic toxicity
Neutropenia 6 (5.0) 4 (3.4) 33 (27.7) 52 (43.7) 24 (20.2)
Anemia 4 (3.4) 27 (22.7) 59 (49.6) 28 (23.5) 1 (0.8)
Thrombocytopenia 49 (41.2) 43 (36.1) 17 (14.3) 9 (7.6) 1 (0.8)
Nonhematologic toxicity
Infection (without neutropenia) 113 (95.0) 0 (0) 0 (0) 3 (2.5) 3 (2.5)
Infection (with neutropenia) 116 (97.5) 0 (0) 0 (0) 1 (0.8) 2 (1.7)
AST 87 (73.1) 29 (24.4) 1 (0.8) 1 (0.8) 1 (0.8)
ALT 83 (69.7) 29 (24.4) 4 (3.4) 2 (1.7) 1 (0.8)
Asthenia 2 (1.7) 29 (24.4) 85 (24.4) 3 (2.5) 0 (0.0)
Alopecia 11 (9.2) 73 (61.3) 35 (2.94) 0 (0.0) 0 (0.0)
Anorexia 0 (0.0) 40 (33.6) 74 (62.2) 5 (4.2) 0 (0.0)
Nausea/vomiting 8 (6.7) 32 (26.9) 78 (65.6) 0 (0.0) 0 (0.0)
Constipation 49 (41.2) 31 (26.1) 30 (26.1) 9 (7.6) 0 (0.0)
Creatinine 82 (68.9) 35 (29.4) 1 (0.8) 1 (0.8) 0 (0.0)
Diarrhea 21 (17.6) 49 (41.2) 35 (29.4) 14 (11.7) 0 (0.0)
Mucositis 43 (36.1) 54 (45.4) 21 (17.6) 1 (0.8) 0 (0.0)
TABLE 3. Maximal Hematologic and Nonhematologic Toxicity of
Maintenance Chemotherapy per Patient (n  21)
Grade by NCI-CTC Version 2.0
0 1 2 3 4
n (%) n (%) n (%) n (%) n (%)
Hematologic toxicity
Neutropenia 3 (14.3) 4 (19.0) 8 (38.1) 1 (4.8) 5 (23.8)
Anemia 1 (4.8) 6 (28.6) 8 (38.1) 6 (28.6) 0 (0.0)
Thrombocytopenia 8 (38.1) 10 (47.6) 3 (14.3) 0 (0.0) 0 (0.0)
Nonhematologic toxicity
Infection (without neutropenia) 20 (95.2) 0 (0.0) 0 (0.0) 1 (4.8) 0 (0.0)
Infection (with neutropenia) 20 (95.2) 0 (0.0) 0 (0.0) 1 (4.8) 0 (0.0)
AST 18 (85.7) 2 (9.5) 1 (4.8) 0 (0.0) 0 (0.0)
ALT 20 (95.2) 0 (0.0) 1 (4.8) 0 (0.0) 0 (0.0)
Asthenia 1 (4.8) 8 (38.1) 12 (57.1) 0 (0.0) 0 (0.0)
Alopecia 1 (4.8) 7 (33.3) 13 (61.9) 0 (0.0) 0 (0.0)
Anorexia 1 (4.8) 6 (28.6) 14 (66.7) 0 (0.0) 0 (0.0)
Nausea/vomiting 6 (28.6) 2 (9.5) 13 (61.9) 0 (0.0) 0 (0.0)
Constipation 12 (57.1) 6 (28.6) 3 (14.3) 0 (0.0) 0 (0.0)
Creatinine 11 (52.4) 10 (47.6) 0 (0.0) 0 (0.0) 0 (0.0)
Diarrhea 4 (19.0) 7 (33.3) 9 (42.9) 1 (4.8) 0 (0.0)
Mucositis 15 (71.4) 5 (23.8) 1 (4.8) 0 (0.0) 0 (0.0)
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vival rates were 59.2% (95% CI, 50.4–68.0) and 17.8% (95%
CI, 10.4–25.2), respectively, as shown in Table 5. Median
PFS was 7.2 months (95% CI, 6.4–8.0) with 1- and 2-year
PFS rates were 20.3% (95% CI, 13.0–27.6) and 6.2% (95%
CI, 1.5–10.9), respectively. Figures 2 and 3 show the pro-
gression-free and OS curves for the patients who participated
in the maintenance versus observation study.
Second-Line Therapy
Overall, 77 patients received salvage chemotherapy after
PD, including 14 of 21 patients (66.7%) in the maintenance arm,
and 19 of 24 patients (79.2%) in the observation arm. The most
commonly used regimens were IP, AIV (adriamycin, ifosf-
amide, and vincristine), CAV (cyclophosphamide, adriamycin,
and vincristine), etoposide and cisplatin, paclitaxel and gemcit-
abine, and others. Table 6 summarized the commonly used
second-line treatments and their response rates.
DISCUSSION
Encouraged by a phase III trial results that had showed
better survival outcome after IP chemotherapy when com-
pared with EP, we previously reported promising activity of
IP regimen for LD-SCLC and also for ED-SCLC.27,28 In this
study, overall response rate was 83% with a CR rate of 10%.
The median survival was 14 months (95% CI, 12.2–15.7)
with 1- and 2-year survival rates of 59.2 and 17.8%. The
median PFS was 7.2 months with 1- and 2-year PFS rates of
20.3 and 6.2%. These results are comparable with those of
two studies of IP regimen for ED-SCLC, which have reported
a median survival time of 13 and 12.8 months.21,22 In addi-
tion, they are better than those of recent standard EP chemo-
therapy. Two recent studies of EP regimen have reported a
median survival of 8.9 and 10.2 months.22,23 Indeed, these
findings suggest that there was significant progress in the
treatment of SCLC with the introduction of IP regimen.
FIGURE 2. Kaplan–Meier plot for time to progression by
randomization.
FIGURE 3. Kaplan–Meier plot for overall survival by ran-
domization.
TABLE 5. Median Progression-Free and Overall Survival
Times
PFS (95% CI) OS (95% CI)
Overall n  120 n  120
Median (mo) 7.2 (6.4–8.0) 14.0 (12.5–15.7)
1 yr (%) 20.3 (13.0–27.6) 59.2 (50.4–68.0)
2 yr (%) 6.2 (1.5–10.9) 17.8 (10.4–25.2)
Randomization maintenance n  21 n  21
Median (mo) 12.0 (9.0–15.0) 17.6 (16.4–18.8)
1 yr (%) 47.6 (26.2–69.0) 85.7 (70.8–100)
2 yr (%) — 19.6 (0.6–38.6)
Observation n  24 n  24
Median (month) 9.9 (8.5–11.3) 20.5 (12.5–28.5)
1 yr (%) 29.2 (11.0–47.4) 83.3 (68.4–98.2)
2 yr (%) — 33.7 (11.7–55.7)
PFS, progression-free survival; OS, overall survival.
TABLE 4. Responses During Maintenance Irinotecan Single
Therapy Versus Observation
No. of Patients
Maintenance
(n  21)
Observation
(n  24)
Maintained CR 2 2
Maintained PR 7 3
Achieved CR from induction PR 0 0
PD 12 19
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Nevertheless, irinotecan maintenance therapy for responding
patients after six or eight cycles of induction IP chemotherapy
did not further influence either PFS or OS in this study.
The role of maintenance chemotherapy in patients with
SCLC has been debated for many years. So far, three ran-
domized trials have shown a survival benefit of maintenance
chemotherapy.6,8,14 Interestingly, two of them used different
chemotherapy regimens, CAV regimen for induction therapy
and EP regimen for maintenance therapy.8,14 These findings
suggest that addition of a noncross resistant regimen as mainte-
nance therapy may improve the therapeutic efficacy. In addition,
five trials have found improved PFS.12,15,16,18,19 Nevertheless,
most studies failed to detect a benefit for maintenance chemo-
therapy.7,9–11,13,14,17 Nevertheless, a recent meta-analysis on
maintenance therapy in SCLC revealed that maintenance ther-
apy improved 1- and 2-year OS by 9% (from 30 to 39%) and 4%
(from 10 to 14%), respectively. Similarly, 1- and 2-year PFS
were also improved.29 This finding suggests that some questions
about the role of maintenance chemotherapy in SCLC are still
awaiting more definite answers. The emergence of novel tar-
geted agents with different action mechanisms makes the ques-
tions more interesting and has recently been proposed as possi-
ble alternatives to maintenance chemotherapy. Interferons,30,31
metalloproteinase inhibitors,32 and thalidomide,33 have been
evaluated as maintenance therapy in SCLC, however, failed to
prolong survival of patients with SCLC.
Our result regarding the role of maintenance irinotecan
therapy in ED-SCLC patients deserves a word of caution
since full patients accrual target was not reached. The opti-
mum number of chemotherapy in ED-SCLC has not been
clearly defined yet. General consensus is that there is no
obvious improvement in survival when the duration of drug
administration exceeds 6 months.5 Indeed, most randomized
trials of maintenance chemotherapy consisted of four to six
cycles of induction chemotherapy.6–19 In the current study,
initial 40 patients received six cycles of 4-week IP induction.
Because of frequent omission of day 15 irinotecan and delay
in the next cycle of chemotherapy, we changed the schedule
as a 3-week cycle using the same doses of irinotecan and
cisplatin on days 1 and 8. Instead we increased the number of
induction therapy from six to eight cycles to match the whole
duration of induction therapy. Because of the study design in
which randomization took place after six or eight cycles of
induction therapy, many patients became not eligible for
randomization because they went off study mainly due to
disease progression during the initial six to eight cycles of
induction therapy, especially among those patients treated on
schedule B. It is interesting to note that 32 (80%) of 40
patients treated with schedule A received all six cycles of
induction therapy, whereas only 30 (38%) of 80 patients
treated with schedule B received all eight cycles of induction
therapy. It was quite unexpected to see many patients in
schedule B developed PD by the time of response re-evalu-
ation after six cycles of IP chemotherapy. This was the major
reason why we could not accrue the target sample size to
examine the role of irinotecan maintenance therapy even
though we completed the patient accrual as initially planned.
Although our study did not demonstrate the survival benefit
of irinotecan maintenance therapy over six or eight cycles of
IP induction therapy, IP chemotherapy seems to be associated
with better survival than old regimens in SCLC. Therefore,
the value of irinotecan single or IP regimen as maintenance
should be evaluated in larger number of patients with ade-
quate power.
In summary, although IP chemotherapy showed signif-
icant activity and favorable survival outcome in SCLC, main-
taining irinotecan as a single therapy in patients with objec-
tive tumor responses after six or eight cycles of IP
chemotherapy failed to show any additional survival benefit.
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